Grading and staging are terms used by doctors to describe tumors (cancer).
The biopsy result is reported using a measure called a Gleason grade and a Gleason score. Grading is performed by a pathologist who examines the cancerous cells under a microscope and assesses the aggressiveness of these cells.
The Gleason grade describes how fast the cancer might spread. It grades tumors on a scale of 1 through 5. You may have different grades of cancer in one biopsy sample. The two most common grades are added together. This gives you the Gleason score.
The higher your Gleason score, the more likely the cancer can spread beyond the prostate:
Staging describes if a cancer has spread from where it first began.
The following tests may be done to determine whether the cancer has spread:
Sometimes, your doctor can feel a prostate cancer during a rectal exam. However, your doctor will also use other information to help guide treatment and follow-up and give you some idea of what to expect in the future. Other factors the doctor will look at include:
It is important to understand that only if and when you have surgery to remove the prostate gland can you and your doctor know for certain the stage and grade of your prostate cancer.
Treatment depends on many things, including your Gleason score, stage of cancer, and your overall health. Your doctor will discuss your treatment options.
American Urological Association Education and Research, Inc. PSA testing for the pretreatment staging and posttreatment management of prostate cancer: 2013 Revision of 2009 Best Practice Statement. Linthicum, MD: American Urological Association Education and Research, Inc. 2013. Available at: www.auanet.org/common/pdf/education/clinical-guidance/Prostate-Specific-Antigen.pdf. Accessed October 3, 2013.
Loeb S, Carter HB. Early detection, diagnosis, and staging of prostate cancer. In: Wein AJ, Kavoussi LR, Novick AC, et al., eds. Campbell-Walsh Urology. 10th ed. Philadelphia, PA: Elsevier Saunders; 2011:chap 99.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate cancer. Version 4.2013. Available at: www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed October 4, 2013.
National Cancer Institute: PDQ Prostate Cancer Treatment. Bethesda, MD: National Cancer Institute. Date last modified 8/15/2013. Available at: www.cancer.gov/cancertopics/pdq/treatment/prostate/HealthProfessional. Accessed October 4, 2013.
Wilt TJ, MacDonald R, et al. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med. 2008;148(6):435-448.
Updated by: Scott Miller, MD, Urologist in private practice in Atlanta, GA. Also reviewed by David Zieve, MD, MHA, Bethanne Black, and the A.D.A.M. Editorial team.
The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed physician should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. Copyright 1997-2015, A.D.A.M., Inc. Duplication for commercial use must be authorized in writing by ADAM Health Solutions.